Table 2.
Multivariate analysis of overall survival.
| Characteristics at Baseline | Stratification | HR | 95% CI | p Value |
|---|---|---|---|---|
| Alkaline phosphatase (median, 166 IU/L) |
<median ≥median |
Ref 1.47 |
[1.25–1.73] | <0.001 |
| Hemoglobin (median, 12.0 g/dL) |
≥median <median |
Ref 1.62 |
[1.40–1.88] | <0.001 |
| Lactate dehydrogenase (median, 327 IU/L) |
<median ≥median |
Ref 1.22 |
[1.05–1.42] | 0.01 |
| Type of progression | PSA-p RADIO-p PAIN-p |
Ref 1.21 1.44 |
[0.96–1.51] [1.21–1.72] |
<0.001 |
| Neutrophil count (median, 4.7 g/L) |
<median ≥median |
Ref 1.21 |
[1.05–1.39] | 0.009 |
| PSA doubling time (median, 2 months) |
≥median <median |
Ref 1.3 |
[1.13–1.50] | <0.001 |
| PSA level (median, 165.5 ng/mL) |
<median ≥median |
Ref 1.27 |
[1.09–1.47] | 0.002 |
| ECOG PS (Stratification factor) |
0 or 1 2 |
Ref 1.35 |
[1.06–1.71] | 0.01 |
| Measurable disease (Stratification factor) |
Non-measurable measurable |
Ref 1.36 |
[1.17–1.58] | <0.001 |
Multivariate Cox regression analyses with backward elimination (5% level), stratified for the region of treatment (Asia, Europe and Australia, US and Canada, others), ECOG PS: Eastern Cooperative Oncology Group performance score (0–1 vs. 2), and disease status (measurable or not).